SCHEMBL4041859

SCHEMBL4041859

COc1ccc2cc(N)c(=O)oc2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.64
CA9 Q16790 3/20 0.64
CA2 P00918 3/20 0.64
CA1 P00915 2/20 0.64
ALDH1A1 P00352 5/20 0.61
MAOB P27338 5/20 0.61
HPGD P15428 4/20 0.61
GAA P10253 4/20 0.61
GLA P06280 4/20 0.61
SLC16A3 O15427 1/20 0.61
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
KDM4E B2RXH2 5/20 0.60
HSD17B10 Q99714 2/20 0.60
CA3 P07451 2/20 0.60
CA4 P22748 2/20 0.60
CA6 P23280 2/20 0.60
CA7 P43166 2/20 0.60
CA14 Q9ULX7 2/20 0.60
NPC1 O15118 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alcohol SCHEMBL4031818 0.93 ALDH1A1 (0.59) CA12CA9CA2CA1ALDH1A1
SCHEMBL11405408 0.87 CA2 (0.64) CA12CA9CA2CA1ALDH1A1
SCHEMBL8756380 0.83 GLA (0.64) CA12CA9CA2CA1ALDH1A1
SCHEMBL7884546 0.81 KDM4E (0.65) CA12CA9CA2ALDH1A1MAOB
SCHEMBL15842248 0.81 ALDH1A1 (0.63) CA12CA9CA2CA1ALDH1A1
SCHEMBL10305766 0.81 ALDH1A1 (0.63) CA12CA9CA2CA1ALDH1A1
SCHEMBL18474355 0.80 CA9 (0.65) CA12CA9CA2CA1ALDH1A1
SCHEMBL17768961 0.80 ALDH1A1 (0.61) CA12CA9CA2CA1ALDH1A1
SCHEMBL2689564 0.80 CA12 (0.64) CA12CA9CA2CA1ALDH1A1
SCHEMBL8787053 0.80 ALDH1A1 (0.61) CA12CA9CA2CA1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116478143-B Donepezil derivative, preparation method and application thereof 山东第一医科大学(山东省医学科学院) 2025-05-09 CN claimed
CN-116478143-A Donepezil derivative, preparation method and application thereof 山东第一医科大学(山东省医学科学院) 2023-07-25 CN claimed
CN-116478143-B Donepezil derivative, preparation method and application thereof 山东第一医科大学(山东省医学科学院) 2025-05-09 CN disclosed
CN-116478143-A Donepezil derivative, preparation method and application thereof 山东第一医科大学(山东省医学科学院) 2023-07-25 CN disclosed
US-10179175-B2 Isatoic anhydride derivatives and applications thereof THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE (US) 2019-01-15 US disclosed
US-20180110862-A1 ISATOIC ANHYDRIDE DERIVATIVES AND APPLICATIONS THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE 2018-04-26 US disclosed
EP-1392680-B1 SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 BAYER SCHERING PHARMA AG (DE) 2009-07-22 EP disclosed
EP-1392680-B1 SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 BAYER SCHERING PHARMA AG (DE) 2009-07-22 EP disclosed
US-20040254185-A1 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-12-16 US disclosed
EP-1392680-A2 SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 SCHERING AKTIENGESELLSCHAFT (DE) 2004-03-03 EP disclosed
US-20040039019-A1 Selected anthranilaminde pyridinamides and their use as pharmaceutical agents SCHERING AG (DE) 2004-02-26 US disclosed
WO-2002090352-A2 SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 SCHERING AKTIENGESELLSCHAFT (DE) 2002-11-14 WO disclosed
US-4287126-A (2-Oxo-2H-1-benzopyran-3-yl)aminooxoacetic acids and their derivatives WARNER-LAMBERT COMPANY (US) 1981-09-01 US disclosed
US-4210758-A 1,5-Dihydro-1,5-dioxo-N-1H-tetrazol-5-yl-4H-[1]benzopyrano[3,4-b]pyridine-2-carboxamides WARNER-LAMBERT COMPANY (US) 1980-07-01 US disclosed
US-4046769-A 4,10-Dihydro-4,10-dioxo-1H-1-benzopyrano[3,2-b]pyridine-2-carboxylic acids and esters WARNER-LAMBERT COMPANY (US) 1977-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10179175-B2 Isatoic anhydride derivatives and applications thereof AASDHPPT, CA13, CA12 CA12 3/4885CA9 13/4885CA2 10/4885
US-20040039019-A1 Selected anthranilaminde pyridinamides and their use as pharmaceutical agents KDR, FLT1, FLT4 CA12 3633/4885CA9 2684/4885CA2 1354/4885
US-20180110862-A1 ISATOIC ANHYDRIDE DERIVATIVES AND APPLICATIONS THEREOF AASDHPPT, CA13, CA12 CA12 3/4885CA9 13/4885CA2 10/4885
US-20040254185-A1 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 FLT4, KDR, FLT1 CA12 4768/4885CA9 4599/4885CA2 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.